Staff Reports
The World Health Organization has put out an urgent call: more volunteers and more clinical sites are needed now to test new vaccines and treatments against the Bundibugyo strain of Ebola. Cases and deaths are climbing in the Democratic Republic of Congo, and international researchers—backed by CEPI and university labs—are scrambling to move vaccine candidates and therapeutic trials from the lab into people. This is a moment when science and logistics must race the virus, not the other way around.
WHO ramps up the call for volunteers and sites
On the ground, the WHO’s R&D coordination team says it needs more teams and more enrollment capacity so trials can run safely and quickly. A WHO‑led therapeutics platform (PARTNERS) has opened patient enrolment in the DRC to test candidate treatments, and the University of Oxford has launched a Phase‑1 trial of a Bundibugyo vaccine in the U.K. Meanwhile, CEPI has rushed funding to Moderna, IAVI and Oxford to speed several vaccine candidates toward human testing. The message is blunt: there are investigational doses and protocols ready, but no amount of press releases will substitute for boots, beds and willing volunteers.
Trials on the ground and in the lab
These efforts include early safety studies in healthy volunteers in the U.K. and simultaneous therapeutic trials among confirmed patients in affected provinces. The therapeutic platform will evaluate candidates already identified; the Phase‑1 vaccine work measures safety and immune response to tell researchers whether a candidate should move forward. That sequencing is textbook science—Phase‑1 for safety, then larger studies for effectiveness—but it only works if trials actually enroll during an outbreak, while the virus is still transmitting enough that meaningful results can be found.
Why the race matters — and where the problems are
There’s a good reason WHO and partners are sounding alarms for volunteers. Bundibugyo is a different Ebola strain, and existing, licensed vaccines target other species of the virus. That means tailored vaccines and treatments are needed now, not someday. But ramping up means solving harder problems than developing a shot: community trust, ethics, monitoring capacity, and rapid site training. Those are expensive, messy, human things that can’t be fixed by a press conference or a grant announcement alone.
A conservative view: speed without surrendering safety or sovereignty
Conservatives should cheer private labs and universities moving fast, and we should expect transparency and accountability from international bodies asking for volunteers. The WHO can coordinate, CEPI can fund, and drugmakers can manufacture—but local leaders and national governments must be in the driver’s seat for logistics and informed consent. If you want volunteers, make participation safe and clear, not political theater. And while we back rapid action in a real outbreak, Washington and allied partners should make sure American and allied scientists, field teams, and regulatory expertise are fully engaged—because when the world depends on global organizations to act fast, it helps to have countries with the capacity to get things done showing the way.
